Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C

Psoriasis

Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature

J Eur Acad Dermatol Venereol.

Piaserico S, Dapavo P, Conti A, Gisondi P, Russo FP

doi: 10.1111/jdv.14146.

Psoriasis

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Lancet.

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H

doi: 10.1016/S0140-6736(18)31713-6.

COMMENTED

Psoriasis

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Lancet.

Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C

doi: 10.1016/S0140-6736(19)30952-3.

Psoriasis

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis

JAMA Dermatol.

van Vugt LJ, van den Reek JMPA, Hannink G, Coenen MJH, de Jong EMGJ

doi: 10.1001/jamadermatol.

Psoriasis

Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics

Eur J Dermatol

Offidani A, Radi G, Bianchi L, Cannavò SP, Conti A, Gesuita R, Salaffi F, Talamonti M, Campanati A

doi: 10.1684/ejd.2021.4121

Psoriasis

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (≥6 to < 12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study

Br J Dermatol.

Philipp S, Menter A, Nikkels AF, Barber K, Landells I, Eichenfield LF, Song M, Randazzo B, Li S, Hsu MC, Zhu Y, DePrimo S, Paller AS

doi: 10.1111/bjd.19018.

Psoriasis

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

Br J Dermatol.

Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K, IXORA-R Study Group

doi: 10.1111/bjd.19509.

Psoriasis

Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial

Adv Ther

Gottlieb AB, Warren RB, Augustin M, Garcia L, Cioffi C, Peterson L, Pelligra C, Ciaravino V

doi: 10.1007/s12325-021-01836-1

Psoriasis

Absolute and relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes

Acta Derm Venereol.

Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C

doi: 10.2340/00015555-3245.

Related content

Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis

Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (≥6 to < 12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial

Absolute and relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes